GC Biopharma Corp. · KRX:006280
GC Biopharma — Investor Day (January 2024)
13 slides from GC Biopharma's investor day presentation, Jan 31, 2024
Slide 1: 2024 GC Biopharma Investor Day
2024 GC BIlOPHARMA INVESTOR DAY 2024. 1. 31 <> GC Biopharma
Slide 2: Contents
<> GCBiopharma = CONTENTS Business update Alyglo™ US Strategy R&D update @ Alyglo™’s Entry and @ US IGIV Market Opportunity @ R80 Strategy Growth in the U.S. market @ Market Entrance Strategy @ Rare Diseases @ Global Expansion @ Financial Projection © ORNA platform of Current Business @ Growth in Do
Slide 3: Company Snapshot
COMPANY SNAPSHOT Nation’s First Plasma-Derived Product Entering the U.S. marekt Market Leader in Domestic Plasma-Derived Product and Flu Vaccines The Largest Domestic DP CMO Facility (1 Billion Doses Based on Finished Products) Successful Phase 2 Clinical Trial for Recombinant Varicella Vaccine (Bes
Slide 4: Business update
I Business update @ Alyglo™’s Entry and Growth in the US Market @ Global Expansion of Current Businesses © Growth in Domestic Primary Care @ Next-Generation Growth Engine ¢> GC Biopharma
Slide 5: Strategic focus areas
01 01 Successful US Market Y Entry and Growth of Alyglo™ US STRATEGIC FOCUS AREAS 02 Global Growth of High- Margin Products Driving Domestic Primary Care Business 03 Kick start Global CMO Business Through Contracts with Domestic Large Corporations and US/European Companies kes 04 Y Commencing Phase
Slide 6: Alyglo's Entry and Growth in the US Market
01 Alyglo™ ‘s Entry and Growth in the US Market : Opportunity Factor for US Market 0 The World’s Largest 1 IGIV Market?) (unit: B$) Mus olo OF xv Bi : 2022 2030 1) Source : MRB 2021-2030 Report and 2022 US Report GC BIOPHARMA INVESTOR D 02 The World’s Highest- Priced Market") (unit: $/g) 7 X65 48 Br
Slide 7: Target Market
Target Market 1) $224M $126M (×1.8) $182M $19M (×9.8) $179M $70M (×2.6)
Slide 8: Target market (combined)
Target market $585M (Combined $215M ) (×2.7)
Slide 9: Revenue from Our Top Three Products: CV/Endo/GI
Revenue from Our Top Three Products: CV/Endo/GI 80+ 40 Revenue 2018 2019 2020 2021 2022 2023 2024 2025 Domestic Market 520.0 560.0 600.0 650.0 690.0 730.0 770.0 810.0 Size Market Growth 7% 7% 8% 8% 6% 6% 6% 6% Rate
Slide 10: Next-Generation Growth Drive: Expansion of CMO Business
01. > GCBiopharma Next-Generation Growth Drive: Expansion of CMO Business Global Market Size of DP CMO”) Certificates for W&FF Plant High-Growth Market with an Annual Growth Rate of 10% 01 WHO PQ Certification in 2023 02 FDA Certification in 2024 C—1 + = $9B 03 EMA Certification in 2024 L@ | 10% > C
Slide 11: Vaccination rate of people over 50+
Vaccination Rate of People over 50+ Number of People Countries Recombinant Protein (2023) aged 50+ with access Vaccine
Slide 12: Next-Generation Growth Drive: CUREVO Varicella Vaccine
01. > GCBiopharma Next-Generation Growth Drive: CUREVO Varicella Vaccine CRV-101 (Age 50~69, n=55) Type Adjuvanted Recombinant Protein API gE +SLA-SE”) gE + ASO1(MPL +QS21?)) Efficac Demonstrated Non-Inferiority ¥ Compared to Competing Drugs _ Grade 23)(Systemic) : 5.5%| Grade 2(Systemic) : 16.4% Gr
Slide 13: Key Takeaways
01 KEY TAKEAWAYS j 4 * 4 Operational Advancement Successful Entry into Accelerating Profitability of Next-Generation the U.S. market of Current Businesses Growth Drivers Expanding beyond domestic market Expanding global market share for flu and Attaining certificates and commencing leadership in blo